Select Your Region

We noticed you visit this page from United States. Please select your preferred region to continue

skip to content

Country Selector

Based on your location

Europe

North America

Latin America

Asia-Pacific

Healthcare Professional Verification

This section contains medical information for licensed healthcare professionals only. Please confirm your professional status to continue.

Pitfalls and ceveats of A1AT diagnosis

Pitfalls and caveats in α1-antitrypsin deficiency testing: a guide for clinicians.

Publié: 4/30/2021 | Modifié: 8/6/2026

α1-antitrypsin deficiency (AATD) remains the only readily identified genetic cause of chronic obstructive pulmonary disease (COPD). Furthermore, there is growing evidence that even a moderate deficiency increases the risk of lung disease among smokers. Despite these facts, the uptake of testing for AATD in at-risk populations remains low for many reasons, and a lack of clarity among clinicians regarding the most appropriate diagnostic techniques presents a major deterrent.

This 2019 guide for α1-antitrypsin deficiency testing addresses the benefits of A1AT diagnosis, the technical basis of the available diagnostic methods. AAT phenotyping by isolectric focusing is part of the available diagnostic methods and it allows detection of multiple variants of AAT in one assay.

The topics covered should equip clinicians with the core knowledge required to confidently assess patients for AATD and increase the number of AATD testing.

Pitfalls_Publication

Test associated with this resource

Related instrument

This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country. Please contact your local Sebia representative. Information intended for healthcare professionals. Carefully read the instructions in the reagent package inserts and instrument manuals.

A1AT Deficiency Testing: Pitfalls, Caveats and Best Practices | Sebia